Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
76 hedge funds and large institutions have $88.1M invested in Aevi Genomic Medicine Inc in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 6 closing their positions.
1,853% more call options, than puts
Call options by funds: $6.58M | Put options by funds: $337K
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
67% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 15
12% more funds holding
Funds holding: 68 → 76 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $91.7M → $88.1M (-$3.65M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.91M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$745K |
| 3 |
Morgan Stanley
New York
|
+$390K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$386K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$362K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.58M |
| 2 |
QF
QVT Financial
New York
|
-$688K |
| 3 |
SS
Sunbelt Securities
Houston,
Texas
|
-$223K |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$203K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$84K |
GNMX Hedge Fund Activity: Q4 2016 in Review
76 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2016, worth a combined $88.1M — down 4% from $91.7M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new GNMX positions and 6 closed out — a net gain of 8 holders — while 25 added to existing stakes and 15 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.91M. The largest seller was Opaleye Management, cutting an estimated $1.58M.
- 76 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2016, up from 68 in Q3 2016.
- Funds reported $88.1M of Aevi Genomic Medicine Inc stock for Q4 2016, down 4% quarter-over-quarter.
- 14 funds opened new Aevi Genomic Medicine Inc positions in Q4 2016 and 6 closed out, a net change of +8 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q4 2016 was Millennium Management, an estimated $1.91M added.
- The largest Aevi Genomic Medicine Inc seller in Q4 2016 was Opaleye Management, an estimated $1.58M sold.
Based on aggregated 13F filings for Q4 2016.